Despite many women with ovarian cancer showing a good response to PARP inhibitors (PARPi), resistance to this treatment is still a major clinical challenge. Inhibitors of Poly(ADP-Ribose) Glycohydrolase (PARGi) have been developed as an alternative therapy to PARPi, with the first clinical trial recently launched in advanced solid tumors.

Under the supervision of established investigator Dr. Jean-Yves Masson this project will explore how PARGi works in ovarian cancer cells, including its impact on specific DNA repair pathways and genetic alterations. This will contribute to an understanding of how PARGi may be used to treat ovarian cancer in the clinic, and identification of prognostic indicators of response.